Gene Pathway Shields Rat Kidneys From Injury
Patients at risk of kidney damage from interrupted blood flow may one day benefit, though the work so far is limited to animal and cell studies.
Updated on Nov. 7, 2026 in Stroke

Researchers reported in a rat study that silencing a gene called ETS1 protected kidneys from ischemia-reperfusion injury, the tissue damage that occurs when blood flow is cut off and then restored. Related experiments found that two PARP1-inhibiting compounds, Veliparib and PJ34, also reduced kidney damage and improved renal function in rats.
Why it matters
Kidney injury from interrupted and restored blood flow is a recognized complication in several clinical settings, so a protective pathway identified in animal models points to a potential future target for prevention. The findings remain preclinical, so they do not yet change how kidney injury is prevented or treated in people.
This is a preclinical study using a rat model of kidney ischemia-reperfusion injury and human HK2 kidney cells grown under oxygen-glucose deprivation and reoxygenation. The findings are preliminary and have not been tested in human patients.
The details
The researchers found that ETS1 acts as a transcription factor that switches on the PARP1 gene, and that PARP1 expression drives cell death and DNA damage in injured kidney cells. When ETS1 was knocked down, PARP1 transcription was inhibited, apoptosis and DNA damage fell, and inflammatory signals and kidney injury were reduced in rats. Compounds that block PARP1 activity, Veliparib and PJ34, produced similar protective effects, supporting PARP1 as the operative pathway.
Timeline
The article was published as accepted early-access research on November 7, 2026.
Health Landscape
Kidney injury from interrupted blood flow remains a difficult problem with limited targeted preventive options, and most of the research pipeline is still in animal and cell models. This work adds an upstream regulatory target to the PARP-inhibitor approach that has been explored in preclinical kidney injury studies.
This is early laboratory and animal work, so it does not change current kidney care or screening. If you have kidney concerns or are facing a procedure that temporarily reduces blood flow to the kidneys, it is worth discussing your individual risk with your physician.
The takeaway
A gene called ETS1 and the enzyme PARP1 appear to drive kidney damage after blood flow is restored in these animal models, which makes them candidate targets for future research. Population-level guidance has not changed, so keep kidney health questions for your doctor.
Further reading
For broader context on how blood-flow interruption injures organs, see the site's Stroke coverage.
Source note: This article includes information reported by Nature.


